Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stayble Therapeutics ABOSTO:STABL 28 3-Year ROIIC % is -1,317.85 as of Dec. 2025. GuruFocus rates OSTO:STABL with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,323 Biotechnology companies, Stayble Therapeutics AB ranks worse than 94.94% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Stayble Therapeutics AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -1,317.85%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Stayble Therapeutics AB's 3-Year ROIIC % or its related term are showing as below:
OSTO:STABL's 3-Year ROIIC % is ranked worse than 94.94% of 1323
companies
in the Biotechnology industry
Industry Median: -4.85
vs OSTO:STABL: -1317.85
Stayble Therapeutics AB (OSTO:STABL) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Stayble Therapeutics AB 3-Year ROIIC % Related Terms
Stayble Therapeutics AB 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:STABL vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Stayble Therapeutics AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stayble Therapeutics AB 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Stayble Therapeutics AB's 3-Year ROIIC % falls into.
Stayble Therapeutics AB 3-Year ROIIC % Calculation
Stayble Therapeutics AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -6.926 (Dec. 2025) - -24.796 (Dec. 2022) )
/
( 6.267 (Dec. 2025) - 7.623 (Dec. 2022) )
=
17.87
/
-1.356
=
-1,317.85%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Stayble Therapeutics AB (OSTO:STABL) has a 3-Year ROIIC % of -1,317.85 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Stayble Therapeutics AB and its competitors. According to the industry distribution chart, Stayble Therapeutics AB ranks #1256 out of 1323 companies in the Biotechnology industry, placing it in the top 94.9%.
Is Stayble Therapeutics AB's 3-Year ROIIC % too high?
Stayble Therapeutics AB's current 3-Year ROIIC % is -1,317.85. Based on the distribution chart, Stayble Therapeutics AB ranks #1256 out of 1323 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stayble Therapeutics AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Stayble Therapeutics AB's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stayble Therapeutics AB ranks #1256 out of 1323 companies for 3-Year ROIIC %. This places Stayble Therapeutics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Stayble Therapeutics AB and its competitors. Stayble Therapeutics AB's current 3-Year ROIIC % is -1,317.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stayble Therapeutics AB stock overvalued right now?
Stayble Therapeutics AB (OSTO:STABL) has a current 3-Year ROIIC % of -1,317.85. The current 3-Year ROIIC % is -1,317.85. Stayble Therapeutics AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Stayble Therapeutics AB (OSTO:STABL), the current 3-Year ROIIC % is -1,317.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
28GF Score
Get the complete analysis for OSTO:STABL
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:STABL has been successfully added to your 
